Extracellular vesicle derived miRNAs from plasma as promising diagnosis and prognosis biomarkers for neuroblastoma

Quick Facts

  • Publication title: Extracellular vesicle derived miRNAs from plasma as promising diagnosis and prognosis biomarkers for neuroblastoma
  • Journal: iScience
  • Year: 2025
  • DOI: 10.1016/j.isci.2025.113636
  • PMID/PMCID: 41142119; PMC12549392

Research overview

This study identified plasma sEV-derived miRNA biomarkers for NB diagnosis and MYCN status prediction. Small extracellular vesicles (sEVs) carry microRNAs (miRNAs) with promising diagnostic potential.

Key findings

Neuroblastoma (NB) is the most common extracranial solid tumor in children.

MYCN amplification remains a critical indicator of high-risk disease and poor prognosis.

Small extracellular vesicles (sEVs) carry microRNAs (miRNAs) with promising diagnostic potential.

This study identified plasma sEV-derived miRNA biomarkers for NB diagnosis and MYCN status prediction.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis, qPCR validation; the study also used or cited Exosupur®.

Related platforms: Exoomics®, Research Reagents & Tools

Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, qPCR Validation, Research Reagent / Product Supply

Related products or reagents: Exosupur® EV Isolation/Purification Kit

References

Original publication: Extracellular vesicle derived miRNAs from plasma as promising diagnosis and prognosis biomarkers for neuroblastoma iScience. 2025. DOI: 10.1016/j.isci.2025.113636. PMID/PMCID: 41142119; PMC12549392.